|
Jun 25
|
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan
|
|
Jun 24
|
Amicus Therapeutics Publishes Positive PROPEL Study Data for Pompe Disease Treatment
|
|
May 21
|
3 High Growth Tech Stocks In The US Market
|
|
May 4
|
Amicus Therapeutics First Quarter 2025 Earnings: Misses Expectations
|
|
May 2
|
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls
|
|
May 1
|
Dimerix and Amicus to commercialise DMX-200 in US
|
|
May 1
|
Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates
|
|
May 1
|
Amicus Therapeutics: Q1 Earnings Snapshot
|
|
May 1
|
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
|
|
Apr 30
|
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
|
|
Apr 29
|
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline
|
|
Apr 11
|
Is Amicus Therapeutics, Inc. (FOLD) the Best Low Priced Growth Stock To Invest In?
|
|
Apr 10
|
Analysts Expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) To Breakeven Soon
|
|
Apr 8
|
Is Amicus Therapeutics, Inc. (FOLD) the Best Low Cost Stock to Buy According to Billionaires?
|
|
Mar 12
|
Amicus Therapeutics, Inc. (FOLD): Among the Stocks Under $10 With High Upside Potential
|
|
Feb 28
|
US High Growth Tech Stocks With Strong Potential
|
|
Feb 27
|
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025
|
|
Feb 23
|
Why Amicus Therapeutics, Inc. (FOLD) is the Most Oversold Pharma Stock to Buy According to Analysts
|
|
Feb 20
|
FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth
|
|
Feb 20
|
Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics
|